Literature DB >> 19766305

Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy.

Yuki Hori1, Patrick J Stern, Richard O Hynes, Darrell J Irvine.   

Abstract

Local immunotherapies are under investigation for the treatment of unresectable tumors and sites of solid tumor resection to prevent local recurrence. Successful local therapy could also theoretically elicit systemic immune responses against cancer. Here we explored the delivery of therapeutic dendritic cells (DCs), cytokines, or other immunostimulatory factors to tumors via the use of 'self-gelling' hydrogels based on the polysaccharide alginate, injected peritumorally around established melanoma lesions. Peritumoral injection of alginate matrices loaded with DCs and/or an interleukin-15 superagonist (IL-15SA) around 14-day established ova-expressing B16F0 murine melanoma tumors promoted immune cell accumulation in the peritumoral matrix, and matrix infiltration correlated with tumor infiltration by leukocytes. Single injections of IL-15SA-carrying gels concentrated the cytokine in the tumor site approximately 40-fold compared to systemic injection and enabled a majority of treated animals to suppress tumor growth for a week or more. Further, we found that single injections of alginate matrices loaded with IL-15SA and the Toll-like receptor ligand CpG or two injections of gels carrying IL-15SA alone could elicit comparable anti-tumor activity without the need for exogenous DCs. Thus, injectable alginate gels offer an attractive platform for local tumor immunotherapy, and facilitate combinatorial treatments designed to promote immune responses locally at a tumor site while limiting systemic exposure to potent immunomodulatory factors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19766305      PMCID: PMC2788234          DOI: 10.1016/j.biomaterials.2009.08.037

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  47 in total

1.  In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity.

Authors:  N K Egilmez; Y S Jong; M S Sabel; J S Jacob; E Mathiowitz; R B Bankert
Journal:  Cancer Res       Date:  2000-07-15       Impact factor: 12.701

2.  Transformation of the microvascular system during multistage tumorigenesis.

Authors:  Eduard Ryschich; Jan Schmidt; Günter J Hämmerling; Ernst Klar; Ruth Ganss
Journal:  Int J Cancer       Date:  2002-02-20       Impact factor: 7.396

3.  Critical role of IL-15-IL-15R for antigen-presenting cell functions in the innate immune response.

Authors:  T Ohteki; K Suzue; C Maki; T Ota; S Koyasu
Journal:  Nat Immunol       Date:  2001-12       Impact factor: 25.606

4.  Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.

Authors:  Steve A Broomfield; Robbert G van der Most; Amy C Prosser; Sathish Mahendran; Michael G Tovey; Mark J Smyth; Bruce W S Robinson; Andrew J Currie
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

5.  Human dendritic cells respond to Porphyromonas gingivalis LPS by promoting a Th2 effector response in vitro.

Authors:  Ravi Jotwani; Bali Pulendran; Sudhanshu Agrawal; Christopher W Cutler
Journal:  Eur J Immunol       Date:  2003-11       Impact factor: 5.532

6.  In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 therapy.

Authors:  Gert W Bos; John J L Jacobs; Jan Willem Koten; Sophie Van Tomme; Theo Veldhuis; Cornelus F van Nostrum; Willem Den Otter; Wim E Hennink
Journal:  Eur J Pharm Sci       Date:  2004-03       Impact factor: 4.384

7.  Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.

Authors:  Katsuyoshi Furumoto; Luis Soares; Edgar G Engleman; Miriam Merad
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

8.  Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration.

Authors:  Mathias Heikenwalder; Magdalini Polymenidou; Tobias Junt; Christina Sigurdson; Hermann Wagner; Shizuo Akira; Rolf Zinkernagel; Adriano Aguzzi
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

9.  Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells.

Authors:  M Mohamadzadeh; F Berard; G Essert; C Chalouni; B Pulendran; J Davoust; G Bridges; A K Palucka; J Banchereau
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

10.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.

Authors:  K Inaba; M Inaba; N Romani; H Aya; M Deguchi; S Ikehara; S Muramatsu; R M Steinman
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

View more
  25 in total

1.  Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity.

Authors:  Myunggi An; Chunsong Yu; Jingchao Xi; Joyce Reyes; Guangzhao Mao; Wei-Zen Wei; Haipeng Liu
Journal:  Nanoscale       Date:  2018-05-17       Impact factor: 7.790

Review 2.  Engineering New Approaches to Cancer Vaccines.

Authors:  Naveen K Mehta; Kelly D Moynihan; Darrell J Irvine
Journal:  Cancer Immunol Res       Date:  2015-07-08       Impact factor: 11.151

Review 3.  Enhancing cancer immunotherapy with nanomedicine.

Authors:  Darrell J Irvine; Eric L Dane
Journal:  Nat Rev Immunol       Date:  2020-01-31       Impact factor: 53.106

4.  Convergence of Highly Resolved and Rapid Screening Platforms with Dynamically Engineered, Cell Phenotype-Prescriptive Biomaterials.

Authors:  Neal K Bennett; Anandika Dhaliwal; Prabhas V Moghe
Journal:  Curr Pharmacol Rep       Date:  2016-03-18

Review 5.  Advances in engineering local drug delivery systems for cancer immunotherapy.

Authors:  Peter Abdou; Zejun Wang; Qian Chen; Amanda Chan; Daojia R Zhou; Vivienne Gunadhi; Zhen Gu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-04-07

Review 6.  Functional and Biomimetic Materials for Engineering of the Three-Dimensional Cell Microenvironment.

Authors:  Guoyou Huang; Fei Li; Xin Zhao; Yufei Ma; Yuhui Li; Min Lin; Guorui Jin; Tian Jian Lu; Guy M Genin; Feng Xu
Journal:  Chem Rev       Date:  2017-10-09       Impact factor: 60.622

Review 7.  Nanomedicine and macroscale materials in immuno-oncology.

Authors:  Qingxue Sun; Matthias Barz; Bruno G De Geest; Mustafa Diken; Wim E Hennink; Fabian Kiessling; Twan Lammers; Yang Shi
Journal:  Chem Soc Rev       Date:  2019-01-02       Impact factor: 54.564

8.  In Vivo Modulation of Dendritic Cells by Engineered Materials: Towards New Cancer Vaccines.

Authors:  Jaeyun Kim; David J Mooney
Journal:  Nano Today       Date:  2011-10       Impact factor: 20.722

Review 9.  Synthetic immune niches for cancer immunotherapy.

Authors:  Jorieke Weiden; Jurjen Tel; Carl G Figdor
Journal:  Nat Rev Immunol       Date:  2017-08-30       Impact factor: 53.106

Review 10.  Bioengineering strategies to accelerate stem cell therapeutics.

Authors:  Christopher M Madl; Sarah C Heilshorn; Helen M Blau
Journal:  Nature       Date:  2018-05-16       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.